| | | Morningstar Overall Rating: |  | | Total Assets: | 830.00K | | Category: | Health | | Total Expense Ratio: | % |
|
| PERFORMANCE & RISK | 30-Nov-09 |
| YTD Return: | 4.17% | | 5y Avg Return: | 4.56% | | Rank in Category (ytd): | 158 | | % Rank in Category (ytd): | 95.76% | | Beta (3y): | 0.35 | | Morningstar Risk Rating: | Low |
|
| The investment seeks long-term growth of capital. The fund usually invests at least 95% of assets in common stocks of companies listed on the AMIDEX-TM- Cancer Innovations & Healthcare index. The Index tracks the performance of publicly traded biotechnology, pharmaceutical and medical equipment companies that emphasize products and services focused on cancer detection and treatment. It employs a passive management approach to invest assets. The fund may also invest in foreign securities that are traded on a U.S. exchange or in a form of American Depository Receipts. The fund is nondiversified. | | | Fund Profile |
|
Help
0.04 (0.60%) 
Summary
Add CNCRX to Portfolio 
Download Data
